Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Common Equity (2020 - 2025)

Roivant Sciences' Common Equity history spans 6 years, with the latest figure at $4.3 billion for Q4 2025.

  • For Q4 2025, Common Equity fell 22.88% year-over-year to $4.3 billion; the TTM value through Dec 2025 reached $4.3 billion, down 22.88%, while the annual FY2025 figure was $5.2 billion, 19.56% down from the prior year.
  • Common Equity reached $4.3 billion in Q4 2025 per ROIV's latest filing, down from $4.8 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $6.6 billion in Q4 2023 to a low of $1.3 billion in Q3 2023.
  • Average Common Equity over 5 years is $3.4 billion, with a median of $2.3 billion recorded in 2021.
  • Peak YoY movement for Common Equity: tumbled 37.65% in 2022, then surged 361.38% in 2023.
  • A 5-year view of Common Equity shows it stood at $2.2 billion in 2021, then tumbled by 36.49% to $1.4 billion in 2022, then skyrocketed by 361.38% to $6.6 billion in 2023, then dropped by 15.93% to $5.5 billion in 2024, then fell by 22.88% to $4.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Common Equity are $4.3 billion (Q4 2025), $4.8 billion (Q3 2025), and $4.8 billion (Q2 2025).